Paper37697173
Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-1: the Effects of Metal Ions and Buffers.
Jakaria SM and 2 others. Pharm Res, 2023. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-1: the Effects of Metal Ions and Buffers. Papers, record 37697173. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37697173
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-1: the Effects of Metal Ions and Buffers.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Metals | Major topic |
| Water | Major topic |
| Buffers | |
| Citrates | |
| Citric Acid | |
| Acetates | |
| Hydrogen-Ion Concentration | |
| Solutions | |
| Teicoplanin |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18983853 | Vancomycin forms ligand-mediated supramolecular complexes. | J Mol Biol | 2009 | https://conductscience.org/library/papers/18983853 | PubMed |
| 2 | 9062068 | Interaction of oxytocin with Ca2+: II. Proton magnetic resonance and molecular modeling studies of conformations of the hormone and its Ca2+ complex. | Biopolymers | 1996 | https://conductscience.org/library/papers/9062068 | PubMed |
| 3 | 27354809 | Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). | Ther Clin Risk Manag | 2016 | https://conductscience.org/library/papers/27354809 | PubMed |
| 4 | 37118348 | Strategies To Stabilize Dalbavancin in Aqueous Solutions; Section 3: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Phosphate Buffer with and without Divalent Metal Ions. | Pharm Res | 2023 | https://conductscience.org/library/papers/37118348 | PubMed |
| 5 | 26078847 | Stereocontrolled 1,2-cis glycosylation as the driving force of progress in synthetic carbohydrate chemistry. | Chem Sci | 2015 | https://conductscience.org/library/papers/26078847 | PubMed |
| 6 | 36530576 | Glycopeptide antibiotic drug stability in aqueous solution. | AAPS Open | 2022 | https://conductscience.org/library/papers/36530576 | PubMed |
| 7 | 33473156 | Dalbavancin: novel candidate for COVID-19 treatment. | Cell Res | 2021 | https://conductscience.org/library/papers/33473156 | PubMed |
| 8 | 17083861 | Dalbavancin: a review for dermatologists. | Dermatol Online J | 2006 | https://conductscience.org/library/papers/17083861 | PubMed |
| 9 | 24608916 | Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin. | Org Biomol Chem | 2014 | https://conductscience.org/library/papers/24608916 | PubMed |
| 10 | 34204961 | Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. | Life (Basel) | 2021 | https://conductscience.org/library/papers/34204961 | PubMed |
| 11 | 29363950 | Developments in Glycopeptide Antibiotics. | ACS Infect Dis | 2018 | https://conductscience.org/library/papers/29363950 | PubMed |
| 12 | 20143256 | Stability of protein pharmaceuticals: an update. | Pharm Res | 2010 | https://conductscience.org/library/papers/20143256 | PubMed |
| 13 | 35065769 | Antimicrobial resistance: time to repurpose the Global Fund. | Lancet | 2022 | https://conductscience.org/library/papers/35065769 | PubMed |
| 14 | 15713062 | Oxytocin-receptor binding: why divalent metals are essential. | J Am Chem Soc | 2005 | https://conductscience.org/library/papers/15713062 | PubMed |
| 15 | 14631936 | International Conference on Harmonisation; Stability Data Package for Registration Applications in Climatic Zones III and IV; Stability Testing of New Drug Substances and Products; availability. Notice. | Fed Regist | 2003 | https://conductscience.org/library/papers/14631936 | PubMed |
| 16 | 26942013 | Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. | J Pathog | 2016 | https://conductscience.org/library/papers/26942013 | PubMed |
| 17 | 17964744 | Stabilization of a polypeptide in non-aqueous solvents. | Int J Pharm | 2008 | https://conductscience.org/library/papers/17964744 | PubMed |
| 18 | 25798039 | Medication-induced hypokalemia. | P T | 2015 | https://conductscience.org/library/papers/25798039 | PubMed |
| 19 | 9876591 | Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV. | Drug Dev Ind Pharm | 1998 | https://conductscience.org/library/papers/9876591 | PubMed |
| 20 | 21448747 | A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. | AAPS J | 2011 | https://conductscience.org/library/papers/21448747 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 39771484 | Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39771484 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37697173
GET https://conductscience.org/api/papers/v1/37697173/authors